Injectables: Understanding the Next Opportunity in Pharma Manufacturing

Why Sterile Injectables Matter for Investors

When we think about medicines, tablets and capsules usually come to mind. But some medicines cannot be effectively given through the oral route. This is where injectable medicines become important.

Injectables deliver medicines directly into the body through routes such as intravenous, intramuscular or subcutaneous administration. Because the medicine bypasses the body's natural barriers, manufacturing standards are significantly more stringent than for ordinary oral medicines.

For investors, this makes the injectable business interesting for a simple reason:

Higher manufacturing complexity can create higher entry barriers.

However, not every company manufacturing injectables will have the same economics. The product mix, regulatory approvals, manufacturing capacity, utilisation and customer profile matter significantly.

What Makes Injectables Different?

A sterile injectable has to meet extremely high quality standards.

The product generally needs to be:

• Sterile – free from living microorganisms

• Free from harmful endotoxins

• Free from visible particles

• Compatible with the human body

• Manufactured under tightly controlled conditions

This requires specialised facilities, sophisticated equipment, trained personnel and strong regulatory systems.

For an investor, this means that an injectable manufacturing facility is not simply another pharmaceutical production line.

The cost and time required to build, validate and obtain regulatory approvals can act as a barrier to new competition.

Not All Injectables Are the Same

One of the most important points when analysing this segment is that "injectables" is a broad category.

There are several formats, including:

1. Liquid Vials

These are widely used for hospital medicines, vaccines and several other pharmaceutical products.

They are relatively faster to manufacture compared with more complex formats.

2. Lyophilised Vials

Some medicines are unstable in liquid form.

In such cases, the product can be freeze-dried, or lyophilised, and supplied as a dry powder that is reconstituted before administration.

This process requires specialised freeze-drying equipment and can significantly increase manufacturing complexity.

3. Ampoules

Ampoules are generally used for single-dose medicines and have traditionally been common in several hospital applications.

4. Pre-Filled Syringes and Cartridges

These provide greater convenience and reduce certain handling steps.

They are particularly relevant for products such as biologics, insulin and other specialised therapies.

The investment takeaway:

A company with only basic injectable capacity should not automatically be valued in the same way as a company with capabilities in complex injectables, lyophilisation, pre-filled syringes, oncology or specialised delivery systems.

Why Could the Segment Be Attractive?

1. High Entry Barriers

Sterile manufacturing requires significant investment in facilities, quality systems and regulatory compliance.

This can make entry difficult for smaller or inexperienced manufacturers.

2. Regulatory Approvals Matter

For companies targeting the US, Europe and other regulated markets, manufacturing facilities need to satisfy stringent regulatory requirements.

A strong regulatory track record can therefore become an important competitive advantage.

3. Complex Products Can Offer Better Economics

Simple injectable products can face intense competition.

However, more complex products such as specialised oncology injectables, lyophilised products, pre-filled syringes and certain biologic-related products can have different competitive dynamics.

4. Outsourcing Opportunity

Global pharmaceutical companies increasingly use contract development and manufacturing organisations (CDMOs) for parts of their manufacturing requirements.

This creates an opportunity for Indian companies with the required capabilities, capacity and regulatory approvals.

India's broader CDMO industry is also expected to benefit from global supply-chain diversification and the China-plus-one strategy.

Indian Stocks to Track

Rather than looking at the entire pharma sector, investors can specifically study companies with meaningful exposure to sterile injectables and contract manufacturing.

Gland Pharma

Gland Pharma is one of the most direct listed plays on sterile injectables in India.

The company describes itself as an injectable-focused pharmaceutical company and has capabilities across liquid vials, lyophilised vials, pre-filled syringes, ampoules, bags and ophthalmic products. Its manufacturing network also includes specialised facilities for areas such as oncology.

The company is also expanding into more complex areas including peptides, long-acting injectables, suspensions, hormonal products, pens and cartridges.

What investors should track:

• Capacity utilisation

• US business growth

• New product launches

• CDMO partnerships

• Regulatory compliance

• Complex injectable pipeline

• Margin improvement

Gland also announced a strategic CDMO partnership in August 2026 and a collaboration with Neuland Laboratories for sterile API manufacturing.

Windlas Biotech

Windlas is another company worth tracking from an injectable/CDMO perspective.

The company has been expanding its manufacturing capabilities, including injectable products. Its investor disclosures and FY26 financial information provide a useful base for tracking the progress of this business.

The key question for investors is not simply whether injectable capacity has been added.

It is:

How quickly can the new capacity achieve meaningful utilisation and translate into revenue and profitability?

This distinction is important because a new facility can initially carry fixed costs before volumes scale up.

Caplin Point Laboratories

Caplin Point has built a significant presence in sterile injectables through its subsidiaries, particularly Caplin Steriles.

The company continues to provide regular disclosures around its sterile business and regulatory developments. Its FY26 annual-report materials include separate disclosures for Caplin Steriles.

Investors should particularly monitor:

• US approvals

• Product launches

• Manufacturing utilisation

• ANDA pipeline

• Capex

• Regulatory observations

• Growth in the sterile business

Caplin also disclosed completion of an unannounced USFDA inspection at Caplin Steriles in August 2026.

What Should Investors Check Before Buying an Injectable Stock?

A common mistake is to look only at revenue growth.

For this segment, investors should go deeper.

1. Capacity vs Utilisation

A company may announce a large new facility, but the real question is:

How much of that capacity is actually being used?

Higher utilisation can improve operating leverage because fixed costs are spread across a larger production base.

2. Product Mix

Ask:

What exactly is the company manufacturing?

Basic ampoules and commodity products can have very different economics from:

• Lyophilised injectables

• Oncology products

• Complex generics

• Pre-filled syringes

• Biologics

• Peptides

• Drug-device combinations

3. Regulatory Track Record

For injectable manufacturers, regulatory compliance is critical.

Investors should monitor:

• USFDA inspections

• Warning letters

• Import alerts

• GMP observations

• Remediation progress

• Approval timelines

A regulatory issue can directly affect production, approvals and customer confidence.

4. Customer Concentration

CDMO businesses can benefit from long-term relationships, but excessive dependence on a small number of customers can create risk.

Investors should examine:

Who are the customers, how diversified is the customer base, and how sticky are the contracts?

5. Capex and Return on Capital

Injectable facilities require substantial capital.

Therefore, investors should not look at capex in isolation.

The important question is:

Will the additional capital generate adequate returns once the facility reaches mature utilisation?

This is where ROCE, asset turnover, EBITDA margins and free cash flow become important.

6. Margin Quality

Higher margins are attractive, but investors should understand why margins are improving.

Is it because of:

• Better product mix?

• Higher utilisation?

• New high-value products?

• Cost efficiencies?

• Temporary pricing benefits?

A sustainable margin improvement is more meaningful than a one-quarter jump.

The Bigger Investment Thesis

The injectable opportunity is not simply a story about "more injections being manufactured."

The more interesting part of the investment thesis is the increasing complexity of pharmaceutical manufacturing.

As products become more specialised, manufacturers need:

Technology + regulatory approvals + specialised facilities + manufacturing expertise + customer relationships.

Companies that can combine these capabilities may have stronger competitive positioning than manufacturers competing purely on volume.

At the same time, investors should remember that high entry barriers do not automatically make a stock attractive at any valuation.

A good business can still be an expensive investment.

Key Takeaway for Investors

When analysing injectable-focused pharmaceutical companies, don't stop at:

"Company has an injectable plant."

Instead, ask:

What does it manufacture?

How complex are those products?

What is the capacity utilisation?

Which markets does it serve?

What regulatory approvals does it have?

How much more capex is required?

What return can that capex generate?

Are margins and cash flows improving?

For investors tracking the theme, Gland Pharma, Windlas Biotech and Caplin Point Laboratories provide useful listed-company case studies, while the broader CDMO universe can be studied separately.

The opportunity should ultimately be evaluated company by company rather than treating all injectable manufacturers as one homogeneous group.